GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Shanchun GuoChangde ZhangMadhusoodanan MottamalAhamed HossainJiawang LiuGuangdi WangPublished in: Breast cancer research and treatment (2020)
This study demonstrates GLL398 is an oral SERD that has therapeutic efficacy in clinically relevant breast tumor models.
Keyphrases